AR007020A1 - Tratamiento de asma con tnfr-ig - Google Patents
Tratamiento de asma con tnfr-igInfo
- Publication number
- AR007020A1 AR007020A1 ARP970101876A ARP970101876A AR007020A1 AR 007020 A1 AR007020 A1 AR 007020A1 AR P970101876 A ARP970101876 A AR P970101876A AR P970101876 A ARP970101876 A AR P970101876A AR 007020 A1 AR007020 A1 AR 007020A1
- Authority
- AR
- Argentina
- Prior art keywords
- asthma
- treatment
- tnf
- tnfr
- alpha binding
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108010003189 recombinant human tumor necrosis factor-binding protein-1 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1684296P | 1996-05-08 | 1996-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007020A1 true AR007020A1 (es) | 1999-10-13 |
Family
ID=21779275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101876A AR007020A1 (es) | 1996-05-08 | 1997-05-06 | Tratamiento de asma con tnfr-ig |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0910413A2 (fr) |
| JP (1) | JP2000510113A (fr) |
| KR (1) | KR20000010825A (fr) |
| CN (1) | CN1233189A (fr) |
| AR (1) | AR007020A1 (fr) |
| AU (1) | AU725408B2 (fr) |
| BR (1) | BR9708928A (fr) |
| CA (1) | CA2253557A1 (fr) |
| CO (1) | CO4820397A1 (fr) |
| HR (1) | HRP970224A2 (fr) |
| MA (1) | MA24169A1 (fr) |
| PE (1) | PE70698A1 (fr) |
| TR (1) | TR199802238T2 (fr) |
| WO (1) | WO1997041895A2 (fr) |
| ZA (1) | ZA973843B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2316545A1 (fr) * | 1997-12-29 | 1999-07-08 | Regeneron Pharmaceuticals, Inc. | Nouvel acide nucleique et nouveau polypeptide |
| TR200504220T2 (tr) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| US20010021380A1 (en) * | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| EA009079B1 (ru) * | 2003-02-28 | 2007-10-26 | Арес Трейдинг С.А. | Жидкие составы фактор некроза опухоли-связывающих белков |
| US7335491B2 (en) * | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| NZ576424A (en) | 2006-10-20 | 2012-09-28 | Biogen Idec Inc | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| EP3488851A1 (fr) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Thérapies immunoablatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) * | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| NZ256293A (en) * | 1992-09-15 | 1997-06-24 | Immunex Corp | Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist |
| US5684222A (en) * | 1993-01-22 | 1997-11-04 | Ontario Cancer Institute | Mutant mouse having a disrupted TNFRp55 |
| CA2119089A1 (fr) * | 1993-03-29 | 1994-09-30 | David Banner | Muteines du facteur de necrose tumoral |
| JPH09508140A (ja) * | 1994-07-22 | 1997-08-19 | エフ・ホフマン−ラ ロシュ アーゲー | キメラｔｎｆ結合タンパク質を含有する医薬組成物 |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| IL116436A (en) * | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
-
1997
- 1997-05-02 WO PCT/EP1997/002256 patent/WO1997041895A2/fr not_active Ceased
- 1997-05-02 EP EP97921849A patent/EP0910413A2/fr not_active Withdrawn
- 1997-05-02 CN CN97194455A patent/CN1233189A/zh active Pending
- 1997-05-02 JP JP09539522A patent/JP2000510113A/ja active Pending
- 1997-05-02 KR KR1019980708961A patent/KR20000010825A/ko not_active Withdrawn
- 1997-05-02 TR TR1998/02238T patent/TR199802238T2/xx unknown
- 1997-05-02 MA MA24590A patent/MA24169A1/fr unknown
- 1997-05-02 HR HR60/016,842A patent/HRP970224A2/xx not_active Application Discontinuation
- 1997-05-02 BR BR9708928-1A patent/BR9708928A/pt not_active Application Discontinuation
- 1997-05-02 CA CA002253557A patent/CA2253557A1/fr not_active Abandoned
- 1997-05-02 AU AU27764/97A patent/AU725408B2/en not_active Ceased
- 1997-05-05 PE PE1997000351A patent/PE70698A1/es not_active Application Discontinuation
- 1997-05-05 ZA ZA9703843A patent/ZA973843B/xx unknown
- 1997-05-06 AR ARP970101876A patent/AR007020A1/es not_active Application Discontinuation
- 1997-05-07 CO CO97024335A patent/CO4820397A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000010825A (ko) | 2000-02-25 |
| WO1997041895A2 (fr) | 1997-11-13 |
| JP2000510113A (ja) | 2000-08-08 |
| CA2253557A1 (fr) | 1997-11-13 |
| BR9708928A (pt) | 2000-05-09 |
| AU2776497A (en) | 1997-11-26 |
| EP0910413A2 (fr) | 1999-04-28 |
| HRP970224A2 (en) | 1998-04-30 |
| WO1997041895A3 (fr) | 1998-03-12 |
| AU725408B2 (en) | 2000-10-12 |
| MA24169A1 (fr) | 1997-12-31 |
| CO4820397A1 (es) | 1999-07-28 |
| TR199802238T2 (xx) | 1999-02-22 |
| CN1233189A (zh) | 1999-10-27 |
| PE70698A1 (es) | 1998-11-18 |
| ZA973843B (en) | 1997-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200101481T2 (tr) | Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi. | |
| TR200100922T2 (tr) | Aktif maddelerin akciğerler yolu ile tatbik edilmesi. | |
| ES2156839T1 (es) | Medicamento que contiene alginato e implante para tratar la fibrosis. | |
| UA41297C2 (uk) | Похідні індолу, фармацевтична композиція і спосіб лікування | |
| EA199800946A1 (ru) | Концентрированный препарат антител | |
| FI972431A7 (fi) | Sytotoksisten T-lymfosyyttivasteiden induktio | |
| UA52594C2 (uk) | Похідні циклоалканопіридину, суміш їх ізомерів або окремі ізомери, їх солі і n-окиси, спосіб та проміжні сполуки для їх одержання, а також фармацевтична композиція | |
| IL134888A0 (en) | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING THEM AND THERAPEUTIC USE THEREOF | |
| PT1319007E (pt) | Compostos de succinimida heterociclicos fundidos e seus analogos enquanto moduladores da funcao dos receptores hormonais nucleares | |
| PL329802A1 (en) | Derivatives of androstene | |
| WO1999058674A3 (fr) | Procede pour inhiber l'activite osteoclastique | |
| PT777482E (pt) | Composicao de combinacao para utilizacao em doencas imunologicas | |
| EE9700225A (et) | Meetod diabetes mellituse raviks, kasutades KKF | |
| BR0111869A (pt) | Compostos cìclicos fundidos como moduladores da função do receptor para homÈnio nuclear | |
| ES2190205T3 (es) | Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda. | |
| IT8419308A0 (it) | Procedimento per la preparazione di formulazioni galeniche particolarmente per uso farmaceutico, dietetico, cosmetico e diagnostico. | |
| MX9704034A (es) | Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso. | |
| AR007165A1 (es) | Composición farmacéutica para uso oral que contiene diclofenac. | |
| CO4820397A1 (es) | TRATAMIENTO CONTRA EL ASMA CON TNFR -Ig | |
| ECSP972104A (es) | Tratamiento de asma con tnfr - ig | |
| ES2016222A4 (es) | Derivados liquidos de grasas naturales y aceites, procedimiento para su elaboracion y utilizacion. | |
| IL129536A0 (en) | Therapeutic and cosmetic compositions their use and method for the preparation thereof | |
| ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| DK0722325T3 (da) | Præparat til behandling eller forebyggelse af herpes | |
| ES2163001T3 (es) | Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |